Atossa Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atossa Therapeutics, Inc. on June 10, 2026. The filing discloses the entry into a Material Definitive Agreement regarding a registered direct offering of equity securities.
Key Financial Metrics and Transaction Details
- Offering Structure: Sale of 1,363,638 shares of Common Stock combined with Series A and Series B warrants to purchase an equal number of shares.
- Offering Price: $3.30 per share (combined price for share and warrants).
- Net Proceeds: Approximately $4.1 million expected after deducting placement agent fees and offering expenses.
- Warrant Terms: Exercise price of $4.40 per share; exercisable six months after issuance. Series A warrants expire in 5.5 years; Series B warrants expire in 2 years.
- Potitional Upside: Potential additional gross proceeds of approximately $12 million if all warrants are fully exercised on a cash basis.
- Placement Agent Fees: 7.0% cash fee on gross proceeds (and on warrant exercises), plus up to $50,000 for expense reimbursement and $15,950 for clearing/closing expenses.
- Placement Agent Warrants: Issuance of warrants to purchase approximately 123,000 shares at an exercise price of $4.125 per share.
Material Changes and Use of Proceeds
The filing represents a material change in the company's capital structure through the issuance of new equity and warrants. The company intends to use the net proceeds for the clinical development of its product candidates, working capital, and general corporate purposes. No historical revenue, profit, or cash flow metrics are provided in this specific filing.
Outlook, Risks, and Contingencies
- Warrant Exercise Risk: The filing explicitly states that no assurance can be given that any of the Series Warrants will be exercised or that the company will receive cash proceeds from such exercises.
- Listing Status: The Series Warrants will not be listed on The Nasdaq Capital Market or any other national securities exchange.
- Closing Date: The offering is expected to close on June 12, 2026.
Key Facts for Investor Verification
- Verify the final closing date and actual net proceeds received on or after June 12, 2026.
- Confirm the dilution impact of the 1,363,638 new shares and the associated warrants on existing shareholders.
- Monitor future filings for updates on the clinical development progress funded by these proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and termination rights.